00:12:59 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-10-09 Årsstämma
2025-09-11 Bokslutskommuniké 2025
2025-02-05 Kvartalsrapport 2025-Q2
2024-10-11 X-dag ordinarie utdelning CHEMM 0.00 DKK
2024-10-10 Årsstämma
2024-09-11 Bokslutskommuniké 2024
2024-02-05 Kvartalsrapport 2024-Q2
2023-10-13 X-dag ordinarie utdelning CHEMM 6.00 DKK
2023-10-12 Årsstämma
2023-09-14 Bokslutskommuniké 2023
2023-05-09 15-10 2023-Q3
2023-02-09 Kvartalsrapport 2023-Q2
2022-10-14 X-dag ordinarie utdelning CHEMM 0.00 DKK
2022-10-13 Årsstämma
2022-09-15 Bokslutskommuniké 2022
2022-02-08 Kvartalsrapport 2022-Q2
2021-10-15 X-dag ordinarie utdelning CHEMM 4.00 DKK
2021-10-14 Årsstämma
2021-09-16 Bokslutskommuniké 2021
2021-02-05 Kvartalsrapport 2021-Q2
2020-10-09 X-dag ordinarie utdelning CHEMM 1.50 DKK
2020-10-08 Årsstämma
2020-09-17 Bokslutskommuniké 2020
2020-02-07 Kvartalsrapport 2020-Q2
2020-01-14 X-dag bonusutdelning CHEMM 13
2020-01-13 Extra Bolagsstämma 2020
2019-10-11 X-dag ordinarie utdelning CHEMM 7.50 DKK
2019-10-10 Årsstämma
2019-09-17 Bokslutskommuniké 2019
2019-02-08 Kvartalsrapport 2019-Q2
2018-10-12 X-dag ordinarie utdelning CHEMM 0.00 DKK
2018-10-11 Årsstämma
2018-09-18 Bokslutskommuniké 2018
2018-02-09 Kvartalsrapport 2018-Q2
2017-11-15 Årsstämma
2017-10-13 X-dag ordinarie utdelning CHEMM 0.00 DKK
2017-10-12 Årsstämma
2017-09-19 Bokslutskommuniké 2017
2017-02-10 Kvartalsrapport 2017-Q2
2016-10-14 X-dag ordinarie utdelning CHEMM 0.00 DKK
2016-10-13 Årsstämma
2016-09-20 Bokslutskommuniké 2016
2016-02-26 Kvartalsrapport 2016-Q2
2015-10-09 X-dag ordinarie utdelning CHEMM 0.00 DKK
2015-10-08 Årsstämma
2015-05-15 Kvartalsrapport 2015-Q3
2014-10-10 X-dag ordinarie utdelning CHEMM 0.00 DKK
2014-10-09 Årsstämma
2014-05-15 Kvartalsrapport 2014-Q3
2013-11-15 Kvartalsrapport 2014-Q1
2013-10-11 X-dag ordinarie utdelning CHEMM 0.00 DKK
2013-10-10 Årsstämma
2013-07-25 Extra Bolagsstämma 2013
2013-05-14 Kvartalsrapport 2013-Q3
2012-11-14 Kvartalsrapport 2013-Q1
2012-10-12 X-dag ordinarie utdelning CHEMM 0.00 DKK
2012-10-11 Årsstämma
2012-05-11 Kvartalsrapport 2012-Q3
2011-11-11 Kvartalsrapport 2012-Q1
2011-10-14 X-dag ordinarie utdelning CHEMM 0.00 DKK
2011-10-13 Årsstämma
2011-05-13 Kvartalsrapport 2011-Q3
2010-11-12 Kvartalsrapport 2011-Q1
2010-10-06 X-dag ordinarie utdelning CHEMM 0.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
ChemoMetec är verksamt inom medicinteknik. Bolaget är specialiserat inom design, utveckling och produktion av patenterade instrument för cellräkning och cellanalys. Bolaget samarbetar och stadgar avtal med aktörer som forskningsinstitut, universitet, livsmedelsbolag, sjukhus och specialkliniker. Kunderna återfinns på en global marknad. Bolaget grundades ursprungligen 1997 och har sitt huvudkontor i Alleröd, Danmark.
2023-12-20 14:35:00

ANNOUNCEMENT NO. 248

20 December 2023


Martin Glensbjerg takes up a new role in ChemoMetec

COO and deputy chairman of the board Martin Glensbjerg has decided to step down in ChemoMetec to pass the baton on to the next generation.

From 1 February 2024 until the end of 2024, he will act as Senior Advisor with reference to CEO Rasmus Kofoed. Martin Glensbjerg continues as deputy chairman of the board. In his new role, Martin Glensbjerg will, among other things, participate in the update of ChemoMetec's strategy and also contribute to ensuring a successful anchoring and launch of the upcoming new products, including XcytoMatic 40 and XcytoMatic 30.

At the same time, Martin Helbo Behrens, Deputy COO, is appointed COO, and Bo Melholt Nielsen, Physicist & Project Manager, Chief R&D Officer. Both Martin Helbo Behrens and Bo Melholt Nielsen have been employed at ChemoMetec for a number of years. Before joining as Deputy COO earlier this year, Martin Helbo Behrens was CFO and COO in ChemoMetec's American subsidiary and was part of Group Finance before that. Bo Melholt Nielsen has a strong academic and professional background in physics, especially quantum optics, and as project manager for the development of XcytoMatic 40 and XcytoMatic 30 he has been a significant driving force behind the development of the new generation of products.

Martin Glensbjerg was one of three co-founders when ChemoMetec was established in 1997, and since then he has held a leading position in the company and has made a significant contribution to ensuring that ChemoMetec has today achieved an attractive global market position.

In connection with Martin Glensbjerg's decision chairman of the board, Niels Thestrup, says: "Martin has played a very special role in ChemoMetec, and his eye for combining innovation and business has been a decisive element in building a well-functioning business model – and for the possibility to grow from a start-up to a largecap company. I understand Martin's decision and the background to it. Over a period of time, we have developed several new products which will be launched in the coming period, and we are thus moving into a new phase in the company's life. With the new generation of leaders and exciting products, it is our ambition to ensure ChemoMetec an even stronger position in existing markets and at the same time provide ChemoMetec the opportunity to move into new attractive markets".


For further information

Chairman of the Board Niels Thestrup
Phone: (+45) 3370 2000

CEO Rasmus Kofoed
Phone: (+45) 2672 6819        


About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to www.chemometec.com